Videos

A practical approach to how urologists might best communicate with radiologists and other clinicians regarding mpMRI results for patients with prostate cancer, with an emphasis on optimizing patient care.

“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.

Laura Bukavina, MD, MPH, summarizes a presentation from the 2022 Society of Urologic Oncology Annual Meeting from Sarah P. Psutka, MD, MS.

Dr Andriole shares remaining unmet needs in prostate cancer risk assessment and shares his hopes for the future.

An expert urologist summarizes the available CV and CU data for the various pre-biopsy biomarker test options, and opines on how use of these tests might impact patient risk stratification, subsequent management, and/or health outcomes.

“It’s important for us to get the tools necessary to deal with patients who come with a unique set of difficulties,” says Laura Bukavina, MD, MPH.

“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

"We're trying to figure out how to improve people's relationships with their genitals and like their sexual practices," says Christi Butler, MD.

Dr Chamie shares advice for community urologists treating patients with MIBC.

Karim Chamie, MD, explains how he might approach immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant settings in the future.

Dr Chamie comments on the significant unmet needs and clinical challenges in the management of MIBC.

Karim Chamie, MD, presents the case of a 77-year-old patient with T2N0M0 MIBC and the potential treatment regimen he would suggest.

Dr Chamie describes how he coordinates with medical oncologists after a referral for MIBC, and his strategies for following up with patients.

Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.

Dr Chamie explains how cisplatin eligibility is defined in patients with MIBC and how many patients in his practice receive neoadjuvant cisplatin therapy.

Karim Chamie, MD, presents the case of a 60-year-old patient with stage 3A muscle-invasive bladder cancer (MIBC) and explains her risk of disease recurrence and whether the case is similar to the patients he typically sees in his clinical practice.

“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.

An overview of the steps involved in the clinical application of mpMRI imaging, from image generation to results interpretation and follow-up.

Dr Gershman discusses how prostate imaging has improved over time, and how and when clinicians implement mpMRI in their practice.

“I think my biggest piece of advice would be to get a social worker into your clinic because there's so many things that we can do,” says Mara Markzon, LCSW, ACM-SW.

A brief commentary on how clinical validity (CV) and clinical utility (CU) are measured for pre-biopsy biomarker tests in patients suspected of having prostate cancer, followed by a focused discussion on the available tests in the space.

Dr Andriole shares insight into how he incorporates pre-biopsy biomarker tests into prostate cancer risk assessment in his clinical practice.

“What we found is that the majority of these companies…offered our ‘secret shopper’ testosterone therapy,” says Joshua A. Halpern, MD, MS.

“First and foremost, it’s great that we have multiple lines of therapy for our bladder cancer patients,” says Tanya Dorff, MD.

Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.

“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.

“It's important to continue to speak up about what we have previously deemed controversial or taboo topics, such as family planning, pay disparities, and discrimination,” says Bridget Lang Findlay, MD.

Dr Shore closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing advice for community oncologists.

Neal Shore, MD, FACS, speculates on how the utilization of AR-pathway inhibitors and docetaxel in earlier lines of mCRPC treatment has also influenced treatment with cabazitaxel.

Dr Shore details how he approaches treatment selection between cabazitaxel and radiotherapy for patients with mCRPC.